Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714775 | 1.00 | NMT2 (0.44) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29590365 | 0.95 | SIRT6 (0.45) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29388582 | 0.86 | SIRT6 (0.44) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL30537468 | 0.85 | ERAP2 (0.45) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29569500 | 0.85 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29569342 | 0.85 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29569082 | 0.85 | PTGS1 (0.43) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29871873 | 0.84 | SIRT6 (0.58) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL31099442 | 0.84 | SIRT6 (0.47) | NMT2NMT1SIRT6SIRT1GLO1 | |
| SCHEMBL29531200 | 0.84 | SIRT6 (0.47) | NMT2NMT1SIRT6SIRT1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | claimed |
| EP-3773736-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | Seagen Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-11-14 | — | — | US | claimed |
| WO-2019195665-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-10-10 | — | — | WO | claimed |
| WO-2024129756-A1 | SITE-SPECIFIC ENGINEERED CYSTEINE ANTIBODY DRUG CONJUGATES | SEAGEN INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240123080-A1 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2024036329-A2 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4321522-A1 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | Seagen Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023178289-A2 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | disclosed |
| EP-3773736-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | Seagen Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2019195665-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | NMT2 566/4885NMT1 617/4885SIRT6 3101/4885 |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | NMT2 104/4885NMT1 94/4885SIRT6 2650/4885 |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | NMT2 104/4885NMT1 94/4885SIRT6 2650/4885 |
| US-20240123080-A1 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | AURKC, AURKB, AURKA | NMT2 570/4885NMT1 479/4885SIRT6 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.